Synthesis of star-shaped CuO nanoparticles supported on magnetic functionalized graphene: Catalytic and antibacterial activity

In this study, graphene oxide was modified during consecutive functionalization steps with 1,4-diphenylamine, cyanuric chloride, and ethylenediamine. Then, star-shaped CuO nanoparticles were synthesized on modified graphene oxide using the seed-mediated growth method in which nucleation, growth stages, and reduction of graphene oxide to graphene occurred simultaneously. After ensuring successful synthesis of CuO nanoparticles and to facilitate recycling, a magnetization process was utilized by adding iron oxide nanoparticles. This nanocomposite was characterized by transmission electron microscopy, X-ray powder diffraction, scanning electron microscopy, and Fourier transform infrared spectroscopy. The prepared heterogeneous catalyst was investigated for the reduction of organic dyes in the presence of NaBH₄ as a reducing reagent. The kinetic data obtained for the reduction of methyl orange (MO), methylene blue (MB), 4-nitrophenol (4-NP), and rhodamine 6G (Rh6G) were fitted to first-order rate equations, and the calculated rate constants for the reduction of MO, MB, 4-NP and Rh6G were as follows: −0.091, −0.071, −0.045, and 0.040, respectively. As star-shaped CuO nanoparticles showed a higher antibacterial effect compared to spherical-shaped CuO nanoparticles, the antibacterial activity of star-shaped CuO nanoparticles immobilized on magnetic functionalized graphene was evaluated against Gram-positive and Gram-negative bacteria through an agar well diffusion assay and demonstrated more antibacterial activity against gram-positive bacteria.     

89Zr Labeled Fe3O4@TiO2 Nanoparticles: In Vitro Afffinities with Breast and Prostate Cancer Cells

In this study, Fe₃O₄@TiO₂ nanoparticles were synthesized as a new Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) hybrid imaging agent and radiolabeled with ⁸⁹Zr. In addition, Fe₃O₄ nanoparticles were synthesized and radiolabeled with ⁸⁹Zr. Df-Bz-NCS was used as bifunctional ligand. The nanoconjugates were characterized with transmission electron microscopy, scanning electron microscopy, and dynamic light scattering. Radiolabeling yields were 100%. Breast and prostate cancer cell affinities and cytotoxicity were determined using in vitro cell culture assays. The results demonstrated that Fe₃O₄@TiO₂ nanoparticles are promising for PET/MR imaging. Finally, unlike Fe₃O₄ nanoparticles, Fe₃O₄@TiO₂ nanoparticles showed a fluorescence spectrum at an excitation wavelength of 250 nm and an emission wavelength of 314 nm. Therefore, in addition to bearing the magnetic properties of Fe₃O₄ nanoparticles, Fe₃O₄@TiO₂ nanoparticles display fluorescence emission. This provides them with photodynamic therapy potential. Therefore multimodal treatment was performed with the combination of PDT and RT by using human prostate cancer cell line (PC3). The development of ⁸⁹Zr-Df-Bz-NCS-Fe₃O₄@TiO₂ nanoparticles as a new multifunctional PET/MRI agent with photodynamic therapy and hyperthermia therapeutic ability would be very useful.     

Eco-friendly synthesis of ZnO nanorods using Cycas pschannae plant extract with excellent photocatalytic,antioxidant, and anticancer nanomedicine for lung cancer treatment

The tunable ZnO nanorods (NRs) are produced due to the phytochemicals present in Cycas pschannae leaves which act as reducing and stabilizing agents. The confirmations of the ZnO NRs were validated using different characterization techniques: X-ray diffraction, Fourier transform infrared spectroscopy, Brunauer, Emmett and Teller (BET), scanning electron microscopy–Energy Dispersive X-Ray Analysis (EDX), UV–visible spectroscopy, Raman spectroscopy, and transmission electron microscopy. The ZnO NRs show unique surface area and low particle size. Photocatalytic activity was measured and found to be 50.75% at low concentrations and 78.33% at high concentrations. The antioxidant activity of the ZnO NRs also showed promising results for their use in free radical scavenging. In vitro toxicity studies using zebrafish embryos was performed to evaluate the toxic nature of it and the obtained result confirmed its non-toxic nature. In addition, ZnO anticancer potential was verified using the A549 lung cancer cell line. Cytotoxic assessments of ZnO NRs were performed via 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), and neutral red uptake assays to examine the cell death cycle on the A549 lung cancer cell. Dose-dependent apoptosis and necrosis were confirmed by Lactate dehydrogenase (LDH) assay. It was also confirmed that ZnO NRs induce Reactive oxygen species (ROS) and apoptosis inside cancer (A549) cells via different intrinsic gene expression. Thus, based on this research it is evident that an effective ecofriendly, nontoxic potential anticancer drug can be synthesized using C. pschannae leaf extract.     

Effect of the topology on the antibacterial activity of cationic polythioether synthesized by all-click chemistry

Cationic compounds often serve as antibacterial materials for a wide range of applications. However, the relationship of topology−antibacterial activity has been rarely revealed. Herein, three cationic polythioethers (CPTEs) with hyperbranched topologies are well designed and facilely synthesized via an all-click chemistry strategy (including thiol-ene and epoxy-amine additions). These as-prepared CPTEs were found to exhibited outstanding antibacterial activity against Escherichia coli and Staphylococcus aureus with minimum inhibitory concentrations against E. coli of 7.3, 14.6, and 14.6 μg ml⁻¹, and against S. aureus of 14.6, 29.2, and 29.2 μg ml⁻¹, respectively. The antibacterial activity is coincident with their degree of branching (DB, their DB values of 0.81, 0.48, and 0.27), which is mainly attributed to the inherent three-dimensional structure. The present strategy reveals the relationship of polymer topology and antibacterial activity, providing a novel possibility for designing and/or synthesis of high-efficiency antibacterial agents.     

Stafia-1: a STAT5a-Selective Inhibitor Developed via Docking-Based Screening of in Silico O-Phosphorylated Fragments

We present a new approach for the identification of inhibitors of phosphorylation-dependent protein–protein interaction domains, in which phenolic fragments are adapted by in silico O-phosphorylation before docking-based screening. From a database of 10 369 180 compounds, we identified 85 021 natural product-derived phenolic fragments, which were virtually O-phosphorylated and screened for in silico binding to the STAT3 SH2 domain. Nine screening hits were then synthesized, eight of which showed a degree of in vitro inhibition of STAT3. After analysis of its selectivity profile, the most potent inhibitor was then developed to Stafia-1, the first small molecule shown to preferentially inhibit the STAT family member STAT5a over the close homologue STAT5b. A phosphonate prodrug based on Stafia-1 inhibited STAT5a with selectivity over STAT5b in human leukemia cells, providing the first demonstration of selective in vitro and intracellular inhibition of STAT5a by a small-molecule inhibitor.     

A Maltol-Containing Ruthenium Polypyridyl Complex as a Potential Anticancer Agent

Cancer is one of the main causes of death worldwide. Chemotherapy, despite its severe side effects, is to date one of the leading strategies against cancer. Metal-based drugs present several potential advantages when compared to organic compounds and they have gained trust from the scientific community after the approval on the market of the drug cisplatin. Recently, we reported the ruthenium complex ([Ru(DIP)₂(sq)](PF₆) (where DIP is 4,7-diphenyl-1,10-phenantroline and sq is semiquinonate) with a remarkable potential as chemotherapeutic agent against cancer, both in vitro and in vivo. In this work, we analyse a structurally similar compound, namely [Ru(DIP)₂(mal)](PF₆), carrying the flavour-enhancing agent approved by the FDA, maltol (mal). To possess an FDA approved ligand is crucial for a complex, whose mechanism of action might include ligand exchange. Herein, we describe the synthesis and characterisation of [Ru(DIP)₂(mal)](PF₆), its stability in solutions and under conditions that resemble the physiological ones, and its in-depth biological investigation. Cytotoxicity tests on different cell lines in 2D model and on HeLa MultiCellular Tumour Spheroids (MCTS) demonstrated that our compound has higher activity than cisplatin, inspiring further tests. [Ru(DIP)₂(mal)](PF₆) was efficiently internalised by HeLa cells through a passive transport mechanism and severely affected the mitochondrial metabolism.     

Ligand Taxonomy for Bioinorganic Modeling of Dioxygen-Activating Non-Heme Iron Enzymes

Novel functions emerge from novel structures. To develop efficient catalytic systems for challenging chemical transformations, chemists often seek inspirations from enzymatic catalysis. A large number of iron complexes supported by nitrogen-rich multidentate ligands have thus been developed to mimic oxo-transfer reactivity of dioxygen-activating metalloenzymes. Such efforts have significantly advanced our understanding of the reaction mechanisms by trapping key intermediates and elucidating their geometric and electronic properties. Critical to the success of this biomimetic approach is the design and synthesis of elaborate ligand systems to balance the thermodynamic stability, structural adaptability, and chemical reactivity. In this Concept article, representative design strategies for biomimetic atom-transfer chemistry are discussed from the perspectives of “ligand builders”. Emphasis is placed on how the primary coordination sphere is constructed, and how it can be elaborated further by rational design for desired functions.     

Luminescent PtII and PtIV Platinacycles with Anticancer Activity Against Multiplatinum-Resistant Metastatic CRC and CRPC Cell Models

Platinum-based chemotherapy persists to be the only effective therapeutic option against a wide variety of tumours. Nevertheless, the acquisition of platinum resistance is utterly common, ultimately cornering conventional platinum drugs to only palliative in many patients. Thus, encountering alternatives that are both effective and non-cross-resistant is urgent. In this work, we report the synthesis, reduction studies, and luminescent properties of a series of cyclometallated (C,N,N′)Pt^IV compounds derived from amine–imine ligands, and their remarkable efficacy at the high nanomolar range and complete lack of cross-resistance, as an intrinsic property of the platinacycle, against multiplatinum-resistant colorectal cancer (CRC) and castration-resistant prostate cancer (CRPC) metastatic cell lines generated for this work. We have also determined that the compounds are effective and selective for a broader cancer panel, including breast and lung cancer. Additionally, selected compounds have been further evaluated, finding a shift in their antiproliferative mechanism towards more cytotoxic and less cytostatic than cisplatin against cancer cells, being also able to oxidize cysteine residues and inhibit topoisomerase II, thereby holding great promise as future improved alternatives to conventional platinum drugs.     

DMT1 Inhibitors Kill Cancer Stem Cells by Blocking Lysosomal Iron Translocation

Cancer stem cells (CSC) constitute a cell subpopulation in solid tumors that is responsible for resistance to conventional chemotherapy, metastasis and cancer relapse. The natural product Salinomycin can selectively target this cell niche by directly interacting with lysosomal iron, taking advantage of upregulated iron homeostasis in CSC. Here, inhibitors of the divalent metal transporter 1 (DMT1) have been identified that selectively target CSC by blocking lysosomal iron translocation. This leads to lysosomal iron accumulation, production of reactive oxygen species and cell death with features of ferroptosis. DMT1 inhibitors selectively target CSC in primary cancer cells and circulating tumor cells, demonstrating the physiological relevance of this strategy. Taken together, this opens up opportunities to tackle unmet needs in anti-cancer therapy.     

Bismuth(III) Flavonolates: The Impact of Structural Diversity on Antibacterial Activity,Mammalian Cell Viability and Cellular Uptake

A series of homoleptic and heteroleptic bismuth(III) flavonolate complexes derived from six flavonols of varying substitution have been synthesised and structurally characterised. The complexes were evaluated for antibacterial activity towards several problematic Gram-positive (Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE)) and Gram-negative (Escherichia coli, Pseudomonas aeruginosa) bacteria. The cell viability of COS-7 (monkey kidney) cells treated with the bismuth flavonolates was also studied to determine the effect of the complexes on mammalian cells. The heteroleptic complexes [BiPh(L)₂] (in which L=flavonolate) showed good antibacterial activity towards all of the bacteria but reduced COS-7 cell viability in a concentration-dependent manner. The homoleptic complexes [Bi(L)₃] exhibited activity towards the Gram-positive bacteria and showed low toxicity towards the mammalian cell line. Bismuth uptake studies in VRE and COS-7 cells treated with the bismuth flavonolate complexes indicated that Bi accumulation is influenced by both the substitution of the flavonolate ligands and the degree of substitution at the bismuth centre.